8-K: KORU Medical Systems Reports Strong Q3 Results, Raises Full Year Guidance

KORU Medical Systems announced a 17% increase in third-quarter revenue, driven by double-digit growth and raised its full-year 2024 guidance for revenue, gross margin, and year-end cash balance.

Summary

• KORU Medical Systems reported a 17% increase in net revenue for the third quarter of 2024, reaching $8.2 million.
• The company experienced a 11% growth in its core business and a significant 276% growth in novel therapies compared to the same period last year.
• Gross profit increased by 19% to $5.2 million, with a gross margin of 63%, a 140-basis point improvement year-over-year.
• The company's cash balance at the end of the quarter was $8.8 million, with a year-to-date cash burn of $2.7 million, a 60% improvement over the prior year.
• KORU Medical has raised its full-year 2024 net revenue guidance to $32.75 $33.25 million, representing a 15% 17% growth.
• Full-year gross margin guidance was also raised to 62% 63%, an improvement of 340 440 basis points over the prior year.
• The company also increased its year-end cash balance guidance to greater than $8.8 million.
• Adjusted EBITDA for the quarter was a loss of $0.4 million, an improvement from the $0.9 million loss in the prior year period.
• The company is reiterating its expectation of cash flow breakeven in the fourth quarter of 2024 and cash flow positive for the full year 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved gross margins, reduced cash burn, and raised guidance. The company's performance is exceeding expectations, and the future outlook is optimistic. However, the net loss and negative adjusted EBITDA temper the sentiment slightly.

Positives

• The company achieved its third consecutive quarter of double-digit revenue growth.
• There was significant growth in the novel therapies business, indicating successful collaborations and clinical trial progress.
• The company improved its gross margin and operating leverage.
• KORU Medical demonstrated a strong cash position and reduced cash burn.
• The company raised its full-year guidance for revenue, gross margin, and year-end cash balance.
• The company is on track to achieve cash flow breakeven in the fourth quarter of 2024 and be cash flow positive for the full year 2025.
• The company's FreedomEdge system received a 97% nursing preference over manual push for subcutaneous oncology infusion.

Negatives

• The company reported a net loss of $1.6 million for the third quarter of 2024.
• Operating expenses increased by $0.8 million, primarily due to compensation-related costs.
• Adjusted EBITDA was negative at ($0.4) million for the quarter, although an improvement from the prior year.

Risks

• The company faces uncertainties associated with SCIg market growth, prefilled syringe penetration, and plasma supply.
• Clinical trial activity and success, as well as the approval and commercialization of new drug indications, pose potential risks.
• The company's EU certification and the shift to increased healthcare delivery in the home are also factors that could impact results.
• Global health crises, innovation and competition, labor and supply price increases, and inflationary impacts are also potential risks.
• Customer ordering patterns and new patient diagnoses could affect future performance.

Future Outlook

KORU Medical has raised its full-year 2024 net revenue guidance to $32.75 $33.25 million, representing a 15% 17% growth, and expects to achieve cash flow breakeven in the fourth quarter of 2024 and be cash flow positive for the full year 2025.

Management Comments

• Linda Tharby, KORU Medical's President and CEO, stated that the company is pleased to deliver another quarter of strong results representing solid execution by the team across all of our businesses and operations.
• She also noted the strength in the recurring chronic subcutaneous immunoglobulin (SCIg) patient base and continued collaborations in the novel therapies business.

Industry Context

The announcement reflects a positive trend in the medical technology sector, particularly in the area of subcutaneous infusion solutions. The growth in novel therapies aligns with the increasing adoption of subcutaneous administration for various drugs. The company's focus on patient-centric solutions and collaborations with biopharmaceutical companies positions it well in the market.

Comparison to Industry Standards

• KORU Medical's 17% revenue growth in Q3 2024 is strong compared to the average growth rate in the medical device industry, which typically ranges from 5-10%.
• Companies like Insulet (PODD) and Tandem Diabetes Care (TNDM), which focus on drug delivery systems, have seen similar growth rates in specific segments, but KORU's growth in novel therapies is particularly notable.
• The 140-basis point improvement in gross margin is also a positive indicator, as many medical device companies struggle to maintain or improve margins due to rising costs.
• The 60% improvement in cash burn is a significant achievement, as many companies in the medical device sector face challenges in managing cash flow during growth phases.
• The 97% nursing preference for KORU's FreedomEdge system is a strong competitive advantage, as it demonstrates the product's value and ease of use compared to manual alternatives.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and raised guidance.
• Employees may benefit from the company's growth and improved financial performance.
• Customers will benefit from the company's innovative and patient-centric solutions.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower credit risk due to its improved financial position.

Next Steps

• The company will host a conference call and webcast on November 13, 2024, to discuss the results and provide a corporate update.
• KORU Medical will continue to execute against its long-term strategies and growth objectives.
• The company will focus on expanding its recurring chronic SCIg patient base and driving collaborations in its novel therapies business.

Key Dates

Keywords

KORU Medical, Subcutaneous Infusion, Medical Technology, Financial Results, Revenue Growth, Gross Margin, Adjusted EBITDA, Novel Therapies, Cash Flow, Guidance